Bydureon Cancer Risk: Persons Taking The Diabetic Drug Bydureon Should Be Aware of its Potential Pancreatic Cancer Health Risk by Bydureon Cancer Lawyer Jason S. Coomer

Recent scientific studies have shown that several diabetes drugs in the incretin mimetic class including Bydureon (exenatide extended-release) may cause an increased risk of pancreatic cancer.  Persons taking Bydureon (exenatide extended-release) should be aware of the potential danger of pancreatic cancer that they face and discuss the risks of this drug with their health care provider.  If you have been taking the diabetes drug Bydureon (exenatide extended-release) and have been diagnosed with pancreatic cancer or you have lost a loved one from pancreatic cancer that was taking Bydureon (exenatide extended-release), please report the adverse action to the prescribing medical doctor and FDA as soon as possible.  

For persons that have been diagnosed with pancreatic cancer or families that have a loved one that has been diagnosed with pancreatic cancer, please feel free to send an e-mail message to Bydureon Pancreatic Cancer Lawyer Jason Coomer.

Bydureon (exenatide) Is An Incretin Mimetic Class Diabetes Medication

Bydureon (exenatide extended-release) is expected to be a blockbuster selling drug with sales of over $1 billion annually.  Though Bydureon (exenatide extended-release) is a relatively new diabetes drug developed by Amylin Pharmaceuticals, Eli Lilly and Alkermes, it has been received approval in the United States and Europe and is expected to be aggressively marketed and sold throughout the World.  A key selling point for Bydureon (exenatide extended-release) is that it is the first FDA-approved drug from the Incretin Mimetic Class that is injected once per week.  Victoza by contrast is injected once per day and Byetta is injected twice per day.  

Bydureon (exenatide extended-release) is a long-acting version of the Amylin and Lilly diabetes drug Byetta.  It is expected to compete in the increasingly competitive market for a class of drugs known as the GLP-1 receptor agonists, however, evidence has indicated that this entire class of drugs may cause an increased risk of pancreatic cancer as well as thyroid cancer. This class of drugs also includes Byetta and Victoza.

The main ingredient in both Bydureon and Byetta is exenatide which is a hormone derived from the saliva of the Gila monster, a poisonous lizard found in the Southwestern United States and Mexico.

The Diabetes Drug Market is Over $40 Billion Each Year and Growing Rapidly Encouraging Drug Companies To Push Dangerous Diabetes Drugs For Profits

More than 300 million people worldwide suffer from diabetes, including about 30 million Americans.  In 2010, the global prevalence of diabetes was estimated to have reached 285 million and predicted to reach 438 million by 2030. The corresponding figures for North America were 37.4 million in 2010 and 53.2 million by 2030 and in Europe 55.2 million in 2010 and 66.2 million in 2030.  The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018.

In Addition to Bydureon (Exenatid) Other Diabetes Drugs in the Incretin Mimetic Class May Cause An Increased Risk of Pancreatic Cancer

• For more information on Januvia Cancer Lawsuits, please go to the following web page on Januvia Pancreatic Cancer Lawsuits and Janumet Pancreatic Cancer Lawsuits.

• For more information on Byetta Cancer Lawsuits, please go to the following web page on Byetta Pancreatic Cancer Lawsuits and Exenatide Pancreatic Cancer Lawsuits.

• For more information on Victoza Cancer Lawsuits, please go to the following web page on Victoza Pancreatic Cancer Lawsuits and Victoza Cancer Death Lawsuits.

Pancreatic Cancer Detection: Understanding and Identifying Symptoms of Pancreatic Cancer Can Be Important In Early Detection and Treatment of Pancreatic Cancer Resulting in Higher Pancreatic Cancer Survival Rates

Symptoms of pancreatic cancer can include: dark urine and clay-colored stools, fatigue and weakness, jaundice (a yellow color in the skin, mucus membranes, or eyes), loss of appetite and weight loss, nausea and vomiting, pain or discomfort in the upper part of the belly or abdomen, back pain, blood clots, diarrhea, and indigestion.

Pancreatic cancer is often not detected early on and is often advanced when it is first found.  As such, ninety-five percent of the people diagnosed with this cancer will not be alive 5 years later.  Some patients have pancreatic cancer that can be surgically removed are cured. However, in more than 80% of patients the tumor has already spread and cannot be completely removed at the time of diagnosis.  In the few cases where pancreatic tumors can be removed by surgery. The standard surgical procedure to remove pancreatic tumors is called a Whipple procedure (pancreatoduodenectomy or pancreaticoduodenectomy). This surgery should be done by an experienced surgeon and at a medical center that performs the procedure often. Some studies suggest that the Whipple procedure is best performed at hospitals that do more than five of these surgeries per year.

When the tumor has not spread out of the pancreas, but cannot be removed, radiation therapy and chemotherapy together may be recommended. When the tumor has spread (metastasized) to other organs such as the liver, chemotherapy alone is usually used. The standard chemotherapy drug is gemcitabine, but other drugs may be used. Gemcitabine can help about 25% of patients.

Patients whose tumor cannot be totally removed, but who have a blockage of the tubes that transport bile (biliary obstruction) must have that blockage relieved. There are two approaches including surgery and placement of a tiny metal tube (biliary stent) during ERCP.

Managing pain and other symptoms is an important part of treating advanced pancreatic cancer. Palliative care tams and hospice can help with pain and symptom management, and provide psychological support for patients and their families during the illness.

Bydureon (Exenatid) Pancreatic Cancer Lawyers Handle Defective and Dangerous Drug Litigation

Texas Dangerous Drug Attorney Jason Coomer commonly works with other lawyers throughout Texas, the United States, and the World including Houston Pancreatic Cancer Lawyers, San Antonio Pancreatic Cancer Lawyers, Dallas Pancreatic Cancer Lawyers, New York Diabetes Drug Pancreatic Cancer Lawyers, Chicago Diabetes Drug Pancreatic Cancer Lawyers, and other Texas Pancreatic Cancer Death Lawyers.  By sharing information and working together, his law firm and other firms throughout World are able to provide better representation for their clients.  

If you have lost a loved one from Pancreatic Cancer or have been diagnosed with Pancreatic Cancer; and have been using Onglyza (Saxagliptin), please report the adverse action to the prescribing medical doctor as soon as possible.  For more information on this topic, please feel free to contact Onglyza Pancreatic Cancer Lawyer Jason Coomer or use our online submission form.